

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. **(Currently amended)** A method for treating cancer comprising administering chlorotoxin or a chlorotoxin derivative as a first agent and temozolomide~~at least one chemotherapeutic agent~~ as a second agent, wherein the two agents are administered simultaneously or are administered independently in a fashion that the agents will act at the same time,

wherein the chlorotoxin or chlorotoxin derivative comprises a sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, and SEQ ID No. 7,~~SEQ ID No. 8, SEQ ID No. 13;~~
and

wherein the cancer is a member of the group consisting of human ~~glioblastoma~~glioblastoma multiforme, human malignant melanoma, human prostate tumor, and human small cell lung carcinoma.
2. **(Currently amended)** A method according to claim 1 wherein the chlorotoxin or chlorotoxin derivative is administered prior to administration of temozolomide~~the chemotherapeutic agent~~.
3. **(Currently amended)** A method according to claim 1 wherein the chlorotoxin or chlorotoxin derivative is administered subsequent to administration of temozolomide~~the chemotherapeutic agent~~.
4. **(Currently amended)** A method according to claim 1 wherein chlorotoxin or chlorotoxin derivative is administered simultaneously with temozolomide~~the chemotherapeutic agent~~.

5.-8. (Canceled)

9. (Currently amended) A composition for treating cancer comprising chlorotoxin or a chlorotoxin derivative and temozolomide ~~at least one chemotherapeutic agent~~, wherein the chlorotoxin or chlorotoxin derivative comprises a sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, and SEQ ID No. 7, ~~SEQ ID No. 8, SEQ ID No. 13,~~

10.-11. (Canceled)

12. (Currently amended) A composition according to claim 9, wherein the cancer is a member of the group consisting of human ~~glioblastoma~~ multiforme ~~glioblastoma multiforme~~, human malignant melanoma, human prostate tumor, and human small cell lung carcinoma.

13-17. (Canceled)

18. (Currently amended) A method according to claim 1, wherein the chlorotoxin or chlorotoxin derivative is conjugated to temozolomide ~~at least one chemotherapeutic agent~~.

19.-21. (Canceled)

22. (New) A method according to claim 1, wherein the chlorotoxin or chlorotoxin derivative includes an incorporated radioactive isotope.

23. (New) A method according to claim 22, wherein the radioactive isotope is selected from the group consisting of ^3H , ^{14}C , ^{18}F , ^{19}F , ^{31}P , ^{32}P , ^{35}S , ^{131}I , ^{125}I , ^{64}Cu , ^{187}Re , ^{111}In , ^{90}Y , $^{99\text{m}}\text{Tc}$, and ^{177}Lu .

24. (New) A method according to claim 23, wherein the radioactive isotope is ^{131}I .

25. **(New)** A method for treating cancer comprising administering chlorotoxin as a first agent and temozolomide as a second agent, wherein the two agents are administered simultaneously or are administered independently in a fashion that the agents will act at the same time, wherein the chlorotoxin comprises an incorporated radioactive isotope, and wherein the cancer is selected from the group consisting of glioblastoma multiforme, human malignant melanoma, human prostate cancer, and human small cell lung carcinoma.
26. **(New)** A method according to claim 25, wherein the radioactive isotope is selected from the group consisting of ^3H , ^{14}C , ^{18}F , ^{19}F , ^{31}P , ^{32}P , ^{35}S , ^{131}I , ^{125}I , ^{64}Cu , ^{187}Re , ^{111}In , ^{90}Y , $^{99\text{m}}\text{Tc}$, and ^{177}Lu .
27. **(New)** A method according to claim 26, wherein the radioactive isotope is ^{131}I .
28. **(New)** A method according to claim 25, wherein the cancer is glioblastoma multiforme.